Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Share-based Compensation (2020 - 2025)

Burning Rock Biotech has reported Share-based Compensation over the past 6 years, most recently at $625375.4 for Q1 2025.

  • For Q1 2025, Share-based Compensation fell 93.55% year-over-year to $625375.4; the TTM value through Mar 2025 reached $12.6 million, down 64.27%, while the annual FY2025 figure was $2.0 million, 90.69% down from the prior year.
  • Share-based Compensation for Q1 2025 was $625375.4 at Burning Rock Biotech, down from $1.1 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $13.1 million in Q1 2021 and troughed at $625375.4 in Q1 2025.
  • A 5-year average of $8.9 million and a median of $9.9 million in 2023 define the central range for Share-based Compensation.
  • Biggest five-year swings in Share-based Compensation: surged 2090.46% in 2021 and later crashed 93.55% in 2025.
  • Year by year, Share-based Compensation stood at $9.5 million in 2021, then skyrocketed by 35.7% to $12.9 million in 2022, then dropped by 23.11% to $9.9 million in 2023, then tumbled by 88.74% to $1.1 million in 2024, then crashed by 43.93% to $625375.4 in 2025.
  • Business Quant data shows Share-based Compensation for BNR at $625375.4 in Q1 2025, $1.1 million in Q4 2024, and $1.4 million in Q3 2024.